🔎 Trials Near Me

Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › New Hampshire

Qorannoo klinikaalii Kansara Qara'a Non-Small Cell New Hampshire keessatti

Qorannoo 17 Kansara Qara'a Non-Small Cell f New Hampshire keessatti hirmaatuu jiru.

Magaalota New Hampshire keessatti

Takkalaa qorannoo (Ingiliffa)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center /ID# 277673, Lebanon
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07155187

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT04267848

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Dartmouth-Hitchcock Medical Center, Lebanon
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT06881784

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Dartmouth Hitchcock Medical Center, Lebanon
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06667076

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06890598

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Site, Lebanon
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT06767514

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

  • Dartmouth Hitchcock Medical Center, Lebanon
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT04302025

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • Dartmouth Hitchcock Medical, Lebanon
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT06119581

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT04165798

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT04165070

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Wax-2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Cam-2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
Namoota walitti qabaa jiraSadarkaa 2
18 Minutes · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT06031688

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

  • Dartmouth Hitchcock, Lebanon
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Elb-2026 · NCT06362369

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

  • Dartmouth Hitchcock Medical Center, Lebanon
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Bit-2026 · NCT05948865

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.